FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Neal Rosen

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Breast Neoplasms

Living Beings

Physiology

Phenomena

Phosphorylation

Co-author Network

Publications

TOP 3
Cristina Montero-Conde; Neal Rosen; Sergio Ruiz-Llorente; Mabel Ryder; Eric J Sherman; Agnes Viale; Jose M Dominguez; Ronald A Ghossein; Jeffrey A Knauf; James A Fagin
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas.
Margaret K Callahan; Omar Abdel-Wahab; Young Rock Chung; James J Harding; Virginia M Klimek; Ross L Levine; Taha Merghoub; Raajit Rampal; Neal Rosen; David B Solit; Jedd D Wolchok; Paul B Chapman
Progression of RAS-mutant leukemia during RAF inhibitor treatment.
Piro Lito; Taha Merghoub; Poulikos I Poulikakos; Christine A Pratilas; Margaret K Callahan; Sarat Chandarlapaty; Elisa de Stanchina; James A Fagin; Ensar Halilovic; Alan Huang; Eric W Joseph; Madhavi Tadi; Jedd D Wolchok; Wai Lin Wong; Matthew Zubrowski; Neal Rosen
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Neal Rosen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Cristina Montero-Conde; Neal Rosen; Sergio Ruiz-Llorente; Mabel Ryder; Eric J Sherman; Agnes Viale; Jose M Dominguez; Ronald A Ghossein; Jeffrey A Knauf; James A Fagin
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas.
Cancer discovery 2013;3(5):520-33.
2012: Margaret K Callahan; Omar Abdel-Wahab; Young Rock Chung; James J Harding; Virginia M Klimek; Ross L Levine; Taha Merghoub; Raajit Rampal; Neal Rosen; David B Solit; Jedd D Wolchok; Paul B Chapman
Progression of RAS-mutant leukemia during RAF inhibitor treatment.
The New England journal of medicine 2012;367(24):2316-21.
2012: Piro Lito; Taha Merghoub; Poulikos I Poulikakos; Christine A Pratilas; Margaret K Callahan; Sarat Chandarlapaty; Elisa de Stanchina; James A Fagin; Ensar Halilovic; Alan Huang; Eric W Joseph; Madhavi Tadi; Jedd D Wolchok; Wai Lin Wong; Matthew Zubrowski; Neal Rosen
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas.
Cancer cell 2012;22(5):668-82.
2012: Yan Liu; Ingo K Mellinghoff; Silvia Menendez; Yasuhiko Miyata; Pier Paolo Pandolfi; Neal Rosen; Goro Sashida; Qing-Bai She; Youyang Yang; Hao Yu; Xinyang Zhao; Zhenbang Chen; Anthony Deblasio; Silvana Di giandomenico; Shannon E Elf; Michael Harr; Cyrus V Hedvat; Gang Huang; Hui-Kuan Lin; Fan Liu; Stephen D Nimer
Akt phosphorylates the transcriptional repressor bmi1 to block its effects on the tumor-suppressing ink4a-arf locus.
Science signaling 2012;5(247):ra77.
2012: Gopa Iyer; Steven M Larson; Michael J Morris; Dana Elizabeth Rathkopf; Neal Rosen; Howard I Scher; Lawrence H Schwartz; Susan F Slovin; Tracy Curley; Anthony Delacruz; Merrill J Egorin; Glenn Heller; S Percy Ivy; Macaulay Steers; Qing Ye; David B Solit
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Cancer chemotherapy and pharmacology 2012;69(4):1089-97.
2012: Mario Lacouture; Kathryn O'Reilly; Neal Rosen; David B Solit
Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(3):329-30.
2012: Aphrothiti J Hanrahan; Adriana Heguy; Manickam Janikariman; Tari A King; Douglas A Levine; Narciso Olvera; Neal Rosen; Rita A Sakr; Chris Sander; Stefano Scarperi; Nikolaus Schultz; Qing-Bai She; David R Spriggs; Elisa de Stanchina; Ellen V Stevens; Barry S Taylor; Maggie L Westfal; Manickam Janakiraman; Carol Aghajanian; Dilip D Giri; David B Solit
Genomic complexity and AKT dependence in serous ovarian cancer.
Cancer discovery 2012;2(1):56-67.
2011: Vanessa S Rodrik-Outmezguine; Maurizio Scaltriti; José Baselga; Sarat Chandarlapaty; Sylvie Guichard; Elizabeth Moskatel; Nen C Pagano; Poulikos I Poulikakos; Neal Rosen
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
Cancer discovery 2011;1(3):248-59.
2011: Brett S Carver; Caren Chapinski; John Wongvipat; Haley Hieronymus; Yu Chen; Sarat Chandarlapaty; Vivek K Arora; Carl Le; Jason Koutcher; Howard Scher; Peter T Scardino; Neal Rosen; Charles L Sawyers
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer.
Cancer cell 2011;19(5):575-86.
2011: David B Solit; Neal Rosen
Resistance to BRAF inhibition in melanomas.
The New England journal of medicine 2011;364(8):772-4.
2011: Aime T Franco; Roberta Malaguarnera; Samuel Refetoff; Xiao-Hui Liao; Emma Lundsmith; Shioko Kimura; Catrin Pritchard; Richard Marais; Terry F Davies; Lee S Weinstein; Min Chen; Neal Rosen; Ronald A Ghossein; Jeffrey A Knauf; James A Fagin
Thyrotrophin receptor signaling dependence of Braf-induced thyroid tumor initiation in mice.
Proceedings of the National Academy of Sciences of the United States of America 2011;108(4):1615-20.
2011: Poulikos I Poulikakos; Neal Rosen
Mutant BRAF melanomas--dependence and resistance.
Cancer cell 2011;19(1):11-5.
2011: Sarat Chandarlapaty; Ayana Sawai; Maurizio Scaltriti; Vanessa Rodrik-Outmezguine; Olivera Grbovic-Huezo; Violeta Serra; Pradip K Majumder; Jose Baselga; Neal Rosen
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Cancer cell 2011;19(1):58-71.
2011: Thomas Bachleitner-Hofmann; Mark Y Sun; Chin-Tung Chen; David Liska; Zhaoshi Zeng; Agnes Viale; Adam B Olshen; Martina Mittlboeck; James G Christensen; Neal Rosen; David B Solit; Martin R Weiser
Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(1):122-33.
2010: David B Solit; Neal Rosen
Oncogenic RAF: a brief history of time.
Pigment cell & melanoma research 2010;23(6):760-2.
2010: Ensar Halilovic; Qing-Bai She; Qing Ye; Raymond Pagliarini; William R Sellers; David B Solit; Neal Rosen
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Cancer research 2010;70(17):6804-14.
2010: Eric W Joseph; Christine A Pratilas; Poulikos I Poulikakos; Madhavi Tadi; Weiqing Wang; Barry S Taylor; Ensar Halilovic; Yogindra Persaud; Feng Xing; Agnes Viale; James Tsai; Paul B Chapman; Gideon Bollag; David B Solit; Neal Rosen
The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner.
Proceedings of the National Academy of Sciences of the United States of America 2010;107(33):14903-8.
2010: Qing-Bai She; Ensar Halilovic; Qing Ye; Wei Zhen; Senji Shirasawa; Takehiko Sasazuki; David B Solit; Neal Rosen
4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors.
Cancer cell 2010;18(1):39-51.
2010: Maurizio Scaltriti; Sarat Chandarlapaty; Ludmila Prudkin; Claudia Aura; José Jimenez; Pier Davide Angelini; Gertrudis Sánchez; Marta Guzman; Josep Lluis Parra; Catherine Ellis; Robert Gagnon; Maria Koehler; Henry Gomez; Charles Geyer; David Cameron; Joaquín Arribas; Neal Rosen; José Baselga
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(9):2688-95.
2010: Craig Cherrin; Kathleen M Haskell; Bonnie Howell; Raymond Jones; Karen Leander; Ronald Robinson; Aubrey Watkins; Mark Bilodeau; Jacob Hoffman; Philip Sanderson; George Hartman; Elizabeth Mahan; Thomayant Prueksaritanont; Guoqiang Jiang; Qing-Bai She; Neal Rosen; Laura Sepp-Lorenzino; Deborah DeFeo-Jones; Hans E Huber
An allosteric Akt inhibitor effectively blocks Akt signaling and tumor growth with only transient effects on glucose and insulin levels in vivo.
Cancer biology & therapy 2010;9(7):493-503.
2010: Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Nature 2010;464(7287):427-30.
2010: Jonathan R Dry; Sandra Pavey; Christine A Pratilas; Chris Harbron; Sarah Runswick; Darren Hodgson; Christine Chresta; Rose McCormack; Natalie Byrne; Mark Cockerill; Alexander Graham; Garry Beran; Andrew Cassidy; Carolyn Haggerty; Helen Brown; Gillian Ellison; Judy Dering; Barry S Taylor; Mitchell Stark; Vanessa Bonazzi; Sugandha Ravishankar; Leisl Packer; Feng Xing; David B Solit; Richard S Finn; Neal Rosen; Nicholas K Hayward; Tim French; Paul D Smith
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).
Cancer research 2010;70(6):2264-73.
2010: Sarat Chandarlapaty; M Scaltriti; P Angelini; Q Ye; M Guzman; Clifford Hudis; Larry Norton; David B Solit; Joaquín Arribas; José Baselga; Neal Rosen
Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
Oncogene 2010;29(3):325-34.
2009: Hongbiao Carl Le; Mihaela Lupu; Khushali Kotedia; Neal Rosen; David B Solit; Jason A Koutcher
Proton MRS detects metabolic changes in hormone sensitive and resistant human prostate cancer models CWR22 and CWR22r.
Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine 2009;62(5):1112-9.
2009: Kathryn E O'Reilly; Melanie Warycha; Michael A Davies; Vanessa Rodrik-Outmezguine; Xi Kathy Zhou; Herman Yee; David Polsky; Anna Pavlick; Neal Rosen; Nina Bhardwaj; Gordon Mills; Iman Osman
Phosphorylated 4E-BP1 is associated with poor survival in melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(8):2872-8.
2009: Christine A Pratilas; Barry S Taylor; Qing Ye; Agnes Viale; Chris Sander; David B Solit; Neal Rosen
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(11):4519-24.
2009: Teri N Kreisl; Andrew B Lassman; Paul Mischel; Neal Rosen; Howard I Scher; Julie T Feldstein; David Shaffer; Eric Lis; Lauren E Abrey
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).
Journal of neuro-oncology 2009;92(1):99-105.
2009: Derek S Welsbie; Jin Xu; Yu Chen; Laetitia Borsu; Howard I Scher; Neal Rosen; Charles L Sawyers
Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer.
Cancer research 2009;69(3):958-66.
2009: Gregory J Riely; Naiyer A Rizvi; Mark G Kris; Daniel T Milton; David B Solit; Neal Rosen; Emir Senturk; Christopher G Azzoli; Julie R Brahmer; Francis M Sirotnak; Venkatraman E Seshan; Margaret Fogle; Michelle Ginsberg; Vincent A Miller; Charles Rudin
Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(2):264-70.
2008: David B Solit; Iman Osman; David Polsky; Katherine S Panageas; Adil Daud; James S Goydos; Jerrold B Teitcher; Jedd D Wolchok; F Joseph Germino; Susan E Krown; Daniel G Coit; Neal Rosen; Paul B Chapman
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(24):8302-7.
2008: Christine A Pratilas; Aphrothiti J Hanrahan; Ensar Halilovic; Yogindra Persaud; Junichi Soh; Dhananjay Chitale; Hisayuki Shigematsu; Hiromasa Yamamoto; Ayana Sawai; Manickam Janakiraman; Barry S Taylor; William Pao; Shinichi Toyooka; Marc Ladanyi; Adi Gazdar; Neal Rosen; David B Solit
Genetic predictors of MEK dependence in non-small cell lung cancer.
Cancer research 2008;68(22):9375-83.
2008: Thomas Bachleitner-Hofmann; Mark Y Sun; Chin-Tung Chen; Laura H Tang; Lin Song; Zhaoshi Zeng; Manish A Shah; James G Christensen; Neal Rosen; David B Solit; Martin R Weiser
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Molecular cancer therapeutics 2008;7(11):3499-508.
2008: M F Barginear; Catherine Van Poznak; Neal Rosen; Shanu Modi; Clifford Hudis; D R Budman
The heat shock protein 90 chaperone complex: an evolving therapeutic target.
Current cancer drug targets 2008;8(6):522-32.
2008: Rebecca Leboeuf; Jacqueline E Baumgartner; Miriam Benezra; Roberta Malaguarnera; David B Solit; Christine A Pratilas; Neal Rosen; Jeffrey A Knauf; James A Fagin
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
The Journal of clinical endocrinology and metabolism 2008;93(6):2194-201.
2008: José Baselga; Neal Rosen
Determinants of RASistance to anti-epidermal growth factor receptor agents.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(10):1582-4.
2008: Ayana Sawai; Sarat Chandarlapaty; Heidi Greulich; Mithat Gonen; Qing Ye; Carlos L Arteaga; William R Sellers; Neal Rosen; David B Solit
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Cancer research 2008;68(2):589-96.
2008: Sven Nelander; Weiqing Wang; Björn Nilsson; Qing-Bai She; Christine A Pratilas; Neal Rosen; Peter Gennemark; Chris Sander
Models from experiments: combinatorial drug perturbations of cancer cells.
Molecular systems biology 2008;4():216.
2008: Qing-Bai She; Sarat Chandarlapaty; Qing Ye; Jose Lobo; Kathleen M Haskell; Karen R Leander; Deborah DeFeo-Jones; Hans E Huber; Neal Rosen
Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling.
PloS one 2008;3(8):e3065.
2008: Erik Henke; Jonathan Perk; Jelena Vider; Paola de-Candia; Yvette Chin; David B Solit; Vladimir Ponomarev; Luca Cartegni; Katia Manova-Todorova; Neal Rosen; Robert Benezra
Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo.
Nature biotechnology 2008;26(1):91-100.
2008: Sarat Chandarlapaty; Ayana Sawai; Qing Ye; Anisa Scott; Melanie Silinski; Ken Huang; Pat Fadden; Jeff Partdrige; Steven Hall; Paul Steed; Larry Norton; Neal Rosen; David B Solit
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(1):240-8.
2007: David B Solit; Elmer B Santos; Christine A Pratilas; Jose Lobo; Maxim Moroz; Shangde Cai; Ronald Blasberg; Judith Leopold; Steven M Larson; Neal Rosen
3'-deoxy-3'-[18F]fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition.
Cancer research 2007;67(23):11463-9.
2007: Shanu Modi; Alison T Stopeck; Michael S Gordon; David Mendelson; David B Solit; Rochelle Bagatell; Weining Ma; Jennifer Wheler; Neal Rosen; Larry Norton; Gillian F Cropp; Robert G Johnson; Alison L Hannah; Clifford Hudis
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(34):5410-7.
2007: Paul Workman; Francis Burrows; Len Neckers; Neal Rosen
Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress.
Annals of the New York Academy of Sciences 2007;1113():202-16.
2007: Lao H Saal; Peter Johansson; Karolina Holm; Sofia K Gruvberger-Saal; Qing-Bai She; Matthew Maurer; Susan Koujak; Adolfo Ferrando; Per-Uno Malmstrom; Lorenzo Memeo; Jorma Isola; Pär-Ola Bendahl; Neal Rosen; Hanina Hibshoosh; Markus Ringnér; Ake Borg; Ramon Parsons
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(18):7564-9.
2007: Kenneth Robzyk; Handy Oen; Grant Buchanan; Lisa M Butler; Wayne D Tilley; Atin K Mandal; Neal Rosen; Avrom J Caplan
Uncoupling of hormone-dependence from chaperone-dependence in the L701H mutation of the androgen receptor.
Molecular and cellular endocrinology 2007;268(1-2):67-74.
2007: David B Solit; S Percy Ivy; Catherine Kopil; Rachel Sikorski; Michael J Morris; Susan F Slovin; W Kevin Kelly; Anthony Delacruz; Tracy Curley; Glenn Heller; Steven M Larson; Lawrence H Schwartz; Merrill J Egorin; Neal Rosen; Howard I Scher
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(6):1775-82.
2007: Matthew G Fury; David B Solit; Yungpo Bernard Su; Neal Rosen; Francis M Sirotnak; Robert P Smith; Christopher G Azzoli; Jorge Gomez; Vincent A Miller; Mark G Kris; Barbara A Pizzo; Roxanne Henry; David G Pfister; Naiyer A Rizvi
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2007;59(4):467-75.
2007: David B Solit; Neal Rosen
Targeting HER2 in prostate cancer: where to next?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(3):241-3.
2007: Bradley T Scroggins; Kenneth Robzyk; Dongxia Wang; Monica G Marcu; Shinji Tsutsumi; Kristin Beebe; Robert J Cotter; Sara J Felts; David O Toft; Larry M Karnitz; Neal Rosen; Len Neckers
An acetylation site in the middle domain of Hsp90 regulates chaperone function.
Molecular cell 2007;25(1):151-9.
2007: Lucia Regales; Marissa N Balak; Yixuan Gong; Katerina Politi; Ayana Sawai; Carl Le; Jason A Koutcher; David B Solit; Neal Rosen; Maureen F Zakowski; William Pao
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors.
PloS one 2007;2(8):e810.
2006: Neal Rosen; Qing-Bai She
AKT and cancer--is it all mTOR?
Cancer cell 2006;10(4):254-6.
2006: seungchan yang; Shimian Qu; Marianela Perez-Tores; Ayana Sawai; Neal Rosen; David B Solit; Carlos L Arteaga
Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors.
Cancer research 2006;66(14):6990-7.
2006: Peter Smith-Jones; David B Solit; Farzana Afroze; Neal Rosen; Steven M Larson
Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2006;47(5):793-6.
2006: Kathryn E O'Reilly; Fredi Rojo; Qing-Bai She; David B Solit; Gordon B Mills; Debra Smith; Heidi Lane; Francesco Hofmann; Daniel J Hicklin; Dale L Ludwig; José Baselga; Neal Rosen
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
Cancer research 2006;66(3):1500-8.
2006: Constantine S Mitsiades; Nicholas Mitsiades; Ciaran McMullan; Vassiliki Poulaki; Andrew L Kung; Faith E Davies; Gareth Morgan; Masaharu Akiyama; Reshma Shringarpure; Nikhil C Munshi; Paul G Richardson; Teru Hideshima; Dharminder Chauhan; Xuesong Gu; Charles Bailey; Marie Joseph; Towia Libermann; Neal Rosen; Kenneth C Anderson
Antimyeloma activity of heat shock protein-90 inhibition.
Blood 2006;107(3):1092-100.
2006: David B Solit; Levi A Garraway; Christine A Pratilas; Ayana Sawai; Gad Getz; Andrea Basso; Qing Ye; Jose Lobo; Yuhong She; Iman Osman; Todd R Golub; Judith Leopold; William R Sellers; Neal Rosen
BRAF mutation predicts sensitivity to MEK inhibition.
Nature 2006;439(7074):358-62.
2006: O M Grbovic; Andrea D Basso; Ayana Sawai; Qing Ye; Paul Friedlander; David B Solit; Neal Rosen
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(1):57-62.
2006: David B Solit; Neal Rosen
Hsp90: a novel target for cancer therapy.
Current topics in medicinal chemistry 2006;6(11):1205-14.
2005: Qing-Bai She; David B Solit; Qing Ye; Kathryn E O'Reilly; Jose Lobo; Neal Rosen
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.
Cancer cell 2005;8(4):287-97.
2005: Laura Llauger; Huazhong He; Joungnam Kim; Julia Aguirre; Neal Rosen; Ulf Peters; Peter Davies; Gabriela Chiosis
Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
Journal of medicinal chemistry 2005;48(8):2892-905.
2005: David B Solit; Yuhong She; Jose Lobo; Mark G Kris; Howard I Scher; Neal Rosen; Francis M Sirotnak
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1983-9.
2005: Michael J Morris; Carlos Cordon-Cardo; W Kevin Kelly; Susan F Slovin; Karen Siedlecki; Kevin Regan; Robert S DiPaola; Mohamed M Rafi; Neal Rosen; Howard I Scher
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2005;13(1):6-13.
2005: Robert Benezra; Erik Henke; Alessia Ciarrocchi; Marianna B Ruzinova; David B Solit; Neal Rosen; D Nolan; Vivek Mittal; Paola de-Candia
Induction of complete regressions of oncogene-induced breast tumors in mice.
Cold Spring Harbor symposia on quantitative biology 2005;70():375-81.
2004: Peter R Carroll; June M Chan; Anthony V D'amico; Edward P Gelmann; Peter Iversen; Laurence Klotz; Joel B Nelson; Peter S Nelson; William G Nelson; William K Oh; Neal Rosen; Mark A Rubin; Howard Sandler; William R Sellers; Matthew R Smith; Jianfeng Xu; Mary Carole McMann; Philip W Kantoff
Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and Treatment.
The Journal of urology 2004;172(5 Pt 2):S3-5.
2004: Joungnam Kim; Sara Felts; Laura Llauger; Huazhong He; Henri Huezo; Neal Rosen; Gabriela Chiosis
Development of a fluorescence polarization assay for the molecular chaperone Hsp90.
Journal of biomolecular screening 2004;9(5):375-81.
2004: Zhi-Qiang Yang; Xudong Geng; David B Solit; Christine A Pratilas; Neal Rosen; Samuel J Danishefsky
New efficient synthesis of resorcinylic macrolides via ynolides: establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on Hsp90 as the target.
Journal of the American Chemical Society 2004;126(25):7881-9.
2004: Maria Vilenchik; David B Solit; Andrea Basso; Henri Huezo; Brian Lucas; Huazhong He; Neal Rosen; Claudia Spampinato; Paul Modrich; Gabriela Chiosis
Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90.
Chemistry & biology 2004;11(6):787-97.
2004: Peter Smith-Jones; David B Solit; Timothy Akhurst; Farzana Afroze; Neal Rosen; Steven M Larson
Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors.
Nature biotechnology 2004;22(6):701-6.
2004: Huazhong He; Laura Llauger; Neal Rosen; Gabriela Chiosis
General method for the synthesis of 8-arylsulfanyl adenine derivatives.
The Journal of organic chemistry 2004;69(9):3230-2.
2003: Richard M Enmon; Wei-Hong Yang; Ase M Ballangrud; David B Solit; Glenn Heller; Neal Rosen; Howard I Scher; George Sgouros
Combination treatment with 17-N-allylamino-17-demethoxy geldanamycin and acute irradiation produces supra-additive growth suppression in human prostate carcinoma spheroids.
Cancer research 2003;63(23):8393-9.
2003: Laura Llauger-Bufi; Sara Felts; Henri Huezo; Neal Rosen; Gabriela Chiosis
Synthesis of novel fluorescent probes for the molecular chaperone Hsp90.
Bioorganic & medicinal chemistry letters 2003;13(22):3975-8.
2003: Wanping Xu; Xitong Yuan; Yun Jin Jung; Yongping Yang; Andrea Basso; Neal Rosen; Eun Joo Chung; Jane Trepel; Len Neckers
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Cancer research 2003;63(22):7777-84.
2003: Paola de-Candia; David B Solit; Dilip D Giri; Edi Brogi; Peter M Siegel; Adam B Olshen; William J Muller; Neal Rosen; Robert Benezra
Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(21):12337-42.
2003: David B Solit; Howard I Scher; Neal Rosen
Hsp90 as a therapeutic target in prostate cancer.
Seminars in oncology 2003;30(5):709-16.
2003: Gabriela Chiosis; Brian Lucas; Henri Huezo; David B Solit; Andrea Basso; Neal Rosen
Development of purine-scaffold small molecule inhibitors of Hsp90.
Current cancer drug targets 2003;3(5):371-6.
2003: Henri Huezo; Maria Vilenchik; Neal Rosen; Gabriela Chiosis
Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR.
Chemistry & biology 2003;10(7):629-34.
2003: Roberto Bianco; Incheol Shin; Christoph A Ritter; F Michael Yakes; Andrea Basso; Neal Rosen; Junji Tsurutani; Phillip A Dennis; Gordon B Mills; Carlos L Arteaga
Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors.
Oncogene 2003;22(18):2812-22.
2003: David B Solit; Andrea D Basso; Adam B Olshen; Howard I Scher; Neal Rosen
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol.
Cancer research 2003;63(9):2139-44.
2003: David R Huron; Mercedes E Gorre; Alan J Kraker; Charles L Sawyers; Neal Rosen; Mark M Moasser
A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1267-73.
2003: Kana Yamamoto; Robert M Garbaccio; Shawn J Stachel; David B Solit; Gabriela Chiosis; Neal Rosen; Samuel J Danishefsky
Total synthesis as a resource in the discovery of potentially valuable antitumor agents: cycloproparadicicol.
Angewandte Chemie (International ed. in English) 2003;42(11):1280-4.
2003: Christopher Benz; Gary Clark; Suzanne D Conzen; Ronald Dorn; Suzanne Fuqua; Julie R Gralow; Geoffrey Greene; Ruth Heimann; Samuel Hellman; Marc Lippman; Neal Rosen; Louis Weiner
Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002.
Breast cancer research and treatment 2003;78(1):127-31.
2003: Gabriela Chiosis; Henri Huezo; Neal Rosen; Edward G Mimnaugh; Luke Whitesell; Len Neckers
17AAG: low target binding affinity and potent cell activity--finding an explanation.
Molecular cancer therapeutics 2003;2(2):123-9.
2002: Gabriela Chiosis; Brian Lucas; Alexander A Shtil; Henri Huezo; Neal Rosen
Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase.
Bioorganic & medicinal chemistry 2002;10(11):3555-64.
2002: Andrea D Basso; David B Solit; Gabriela Chiosis; Banabihari Giri; Philip Tsichlis; Neal Rosen
Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function.
The Journal of biological chemistry 2002;277(42):39858-66.
2002: Mercedes E Gorre; Katharine Ellwood-Yen; Gabriela Chiosis; Neal Rosen; Charles L Sawyers
BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.
Blood 2002;100(8):3041-4.
2002: Pamela N Münster; Douglas C Marchion; Andrea D Basso; Neal Rosen
Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway.
Cancer research 2002;62(11):3132-7.
2002: Mark M Moasser; Neal Rosen
The use of molecular markers in farnesyltransferase inhibitor (FTI) therapy of breast cancer.
Breast cancer research and treatment 2002;73(2):135-44.
2002: David B Solit; Fuzhong F Zheng; Marija Drobnjak; Pamela N Münster; Brian Higgins; David Verbel; Glenn Heller; William Tong; Carlos Cordon-Cardo; David B Agus; Howard I Scher; Neal Rosen
17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(5):986-93.
2002: Michael J Morris; William P Tong; Carlos Cordon-Cardo; Marija Drobnjak; W Kevin Kelly; Susan F Slovin; Kathryn L Terry; Karen Siedlecki; Paul Swanson; Mohamed M Rafi; Robert S DiPaola; Neal Rosen; Howard I Scher
Phase I trial of BCL-2 antisense oligonucleotide (G3139) administered by continuous intravenous infusion in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):679-83.
2002: Andrea D Basso; David B Solit; Pamela N Munster; Neal Rosen
Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.
Oncogene 2002;21(8):1159-66.
2001: Pamela N Munster; T Troso-Sandoval; Neal Rosen; Richard A Rifkind; Paul A Marks; Victoria M Richon
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Cancer research 2001;61(23):8492-7.
2001: Brian Lucas; Neal Rosen; Gabriela Chiosis
Facile synthesis of a library of 9-alkyl-8-benzyl-9H-purin-6-ylamine derivatives.
Journal of combinatorial chemistry 2001;3(6):518-20.
2001: Mark M Moasser; Andrea Basso; Steven D Averbuch; Neal Rosen
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Cancer research 2001;61(19):7184-8.
2001: Pamela N Münster; Andrea Basso; David B Solit; Larry Norton; Neal Rosen
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. See: E. A. Sausville, Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters, Clin. Cancer Res., 7: 2155-2158, 2001.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2228-36.
2001: Gabriela Chiosis; Neal Rosen; Laura Sepp-Lorenzino
LY294002-geldanamycin heterodimers as selective inhibitors of the PI3K and PI3K-related family.
Bioorganic & medicinal chemistry letters 2001;11(7):909-13.
2001: Pamela N Münster; M Srethapakdi; Mark M Moasser; Neal Rosen
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
Cancer research 2001;61(7):2945-52.
2001: Gabriela Chiosis; M N Timaul; Brian Lucas; Pamela N Munster; Fuzhong F Zheng; Laura Sepp-Lorenzino; Neal Rosen
A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells.
Chemistry & biology 2001;8(3):289-99.
2000: M Srethapakdi; F Liu; R Tavorath; Neal Rosen
Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.
Cancer research 2000;60(14):3940-6.
2000: SD Kuduk; T C Harris; Fuzhong F Zheng; Laura Sepp-Lorenzino; Q Ouerfelli; Neal Rosen; Samuel J Danishefsky
Synthesis and evaluation of geldanamycin-testosterone hybrids.
Bioorganic & medicinal chemistry letters 2000;10(11):1303-6.
2000: Fuzhong F Zheng; SD Kuduk; Gabriela Chiosis; Pamela N Münster; Laura Sepp-Lorenzino; Samuel J Danishefsky; Neal Rosen
Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.
Cancer research 2000;60(8):2090-4.
2000: Francis M Sirotnak; Laura Sepp-Lorenzino; Nancy E Kohl; Neal Rosen; Howard I Scher
A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility.
Cancer chemotherapy and pharmacology 2000;46(1):79-83.
1999: Mark M Moasser; M Srethapakdi; K S Sachar; Alan J Kraker; Neal Rosen
Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest.
Cancer research 1999;59(24):6145-52.
1999: J L Chou; Z Fan; Tony DeBlasio; Andrew Koff; Neal Rosen; John Mendelsohn
Constitutive overexpression of cyclin D1 in human breast epithelial cells does not prevent G1 arrest induced by deprivation of epidermal growth factor.
Breast cancer research and treatment 1999;55(3):267-83.
1999: SD Kuduk; Fuzhong F Zheng; Laura Sepp-Lorenzino; Neal Rosen; Samuel J Danishefsky
Synthesis and evaluation of geldanamycin-estradiol hybrids.
Bioorganic & medicinal chemistry letters 1999;9(9):1233-8.
1999: Gerhard Zugmaier; R Favoni; R Jaeger; Neal Rosen; Cornelius Knabbe
Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors.
Annals of the New York Academy of Sciences 1999;886():243-8.
1998: Robin C Muise-Helmericks; H Leighton Grimes; Alfonso Bellacosa; SE Malstrom; Philip Tsichlis; Neal Rosen
Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway.
The Journal of biological chemistry 1998;273(45):29864-72.
1998: Laura Sepp-Lorenzino; Neal Rosen
A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.
The Journal of biological chemistry 1998;273(32):20243-51.
1998: Mark M Moasser; Laura Sepp-Lorenzino; Nancy E Kohl; Allen Oliff; Aaron Balog; D S Su; Samuel J Danishefsky; Neal Rosen
Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(4):1369-74.
1996: C Schneider; Laura Sepp-Lorenzino; E Nimmesgern; Ouathek Ouerfelli; Samuel J Danishefsky; Neal Rosen; F Ulrich Hartl
Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(25):14536-41.
1996: Susan F Slovin; Philip O Livingston; Neal Rosen; Laura Sepp-Lorenzino; W Kevin Kelly; J Mendelsohn; Howard I Scher
Targeted therapy for prostate cancer: the Memorial Sloan-Kettering Cancer Center approach.
Seminars in oncology 1996;23(6 Suppl 14):41-8.
1996: Laura Sepp-Lorenzino; I Eberhard; Z Ma; C Cho; Hubert Serve; F Liu; Neal Rosen; R Lupu
Signal transduction pathways induced by heregulin in MDA-MB-453 breast cancer cells.
Oncogene 1996;12(8):1679-87.
1996: Jackson B Gibbs; Nancy E Kohl; Kenneth S Koblan; CA Omer; Laura Sepp-Lorenzino; Neal Rosen; Neville J Anthony; M W Conner; S Jane deSolms; Theresa M Williams; Samuel L Graham; George D Hartman; Allen Oliff
Farnesyltransferase inhibitors and anti-Ras therapy.
Breast cancer research and treatment 1996;38(1):75-83.
1995: Larry Norton; Paul Peter Rosen; Neal Rosen
Refining the origins of breast cancer.
Nature medicine 1995;1(12):1250-1.
1995: Robin C Muise-Helmericks; Neal Rosen
Identification of a novel repressive element in the proximal lck promoter.
The Journal of biological chemistry 1995;270(46):27538-43.
1995: Laura Sepp-Lorenzino; Z Ma; Elaine Rands; Nancy E Kohl; Jackson B Gibbs; Allen Oliff; Neal Rosen
A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
Cancer research 1995;55(22):5302-9.
1995: J M Bentel; David Lebwohl; Kevin J Cullen; M S Rubin; Neal Rosen; J Mendelsohn; W H Miller
Insulin-like growth factors modulate the growth inhibitory effects of retinoic acid on MCF-7 breast cancer cells.
Journal of cellular physiology 1995;165(1):212-21.
1995: Laura Sepp-Lorenzino; Z Ma; David Lebwohl; A Vinitsky; Neal Rosen
Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases.
The Journal of biological chemistry 1995;270(28):16580-7.
1995: X Wu; Z Fan; H Masui; Neal Rosen; J Mendelsohn
Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.
The Journal of clinical investigation 1995;95(4):1897-905.
1994: Laura Sepp-Lorenzino; Neal Rosen; David Lebwohl
Insulin and insulin-like growth factor signaling are defective in the MDA MB-468 human breast cancer cell line.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1994;5(10):1077-83.
1994: Neal Rosen
The molecular basis for cellular transformation: implications for esophageal carcinogenesis.
Seminars in oncology 1994;21(4):416-24.
1994: David Lebwohl; Robin C Muise-Helmericks; Laura Sepp-Lorenzino; S Serve; M Timaul; R Bol; Patrick I Borgen; Neal Rosen
A truncated cyclin D1 gene encodes a stable mRNA in a human breast cancer cell line.
Oncogene 1994;9(7):1925-9.
1994: D Eliyahu; S Evans; Neal Rosen; S Eliyahu; J Zwiebel; Soonmyung Paik; Marc Lippman
p53Val135 temperature sensitive mutant suppresses growth of human breast cancer cells.
Breast cancer research and treatment 1994;30(2):167-77.
1992: Kevin J Cullen; Marc Lippman; D Chow; S Hill; Neal Rosen; J A Zwiebel
Insulin-like growth factor-II overexpression in MCF-7 cells induces phenotypic changes associated with malignant progression.
Molecular endocrinology (Baltimore, Md.) 1992;6(1):91-100.
1991: Kevin J Cullen; H S Smith; S Hill; Neal Rosen; Marc Lippman
Growth factor messenger RNA expression by human breast fibroblasts from benign and malignant lesions.
Cancer research 1991;51(18):4978-85.
1991: Neal Rosen; D Yee; Marc Lippman; Soonmyung Paik; Kevin J Cullen
Insulin-like growth factors in human breast cancer.
Breast cancer research and treatment 1991;18 Suppl 1():S55-62.
1991: D Yee; Neal Rosen; Roberto Favoni; Kevin J Cullen
The insulin-like growth factors, their receptors, and their binding proteins in human breast cancer.
Cancer treatment and research 1991;53():93-106.
1991: Kevin J Cullen; D Yee; Neal Rosen
Insulinlike growth factors in human malignancy.
Cancer investigation 1991;9(4):443-54.
1990: D Yee; Roberto Favoni; G S Lebovic; F Lombana; David R Powell; Charles Patrick Reynolds; Neal Rosen
Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor.
The Journal of clinical investigation 1990;86(6):1806-14.
1990: L D Murphy; E M Valverius; M Tsokos; Lyn A Mickley; Neal Rosen; Susan E Bates
Modulation of EGF receptor expression by differentiating agents in human colon carcinoma cell lines.
Cancer communications 1990;2(10):345-55.
1990: Kevin J Cullen; D Yee; W S Sly; J Perdue; Brian Hampton; Marc Lippman; Neal Rosen
Insulin-like growth factor receptor expression and function in human breast cancer.
Cancer research 1990;50(1):48-53.
1989: D Yee; G S Lebovic; R R Marcus; Neal Rosen
Identification of an alternate type I insulin-like growth factor receptor beta subunit mRNA transcript.
The Journal of biological chemistry 1989;264(36):21439-41.
1989: Soonmyung Paik; Neal Rosen; W Jung; J M You; Marc Lippman; J F Perdue; D Yee
Expression of insulin-like growth factor-II mRNA in fetal kidney and Wilms' tumor. An in situ hybridization study.
Laboratory investigation; a journal of technical methods and pathology 1989;61(5):522-6.
1989: Lyn A Mickley; Susan E Bates; N D Richert; S Currier; S Tanaka; Francine M Foss; Neal Rosen; Antonio Tito Fojo
Modulation of the expression of a multidrug resistance gene (mdr-1/P-glycoprotein) by differentiating agents.
The Journal of biological chemistry 1989;264(30):18031-40.
1989: O Sartor; F S Gregory; N S Templeton; S Pawar; Roger M Perlmutter; Neal Rosen
Selective expression of alternative lck mRNAs in human malignant cell lines.
Molecular and cellular biology 1989;9(7):2983-8.
1989: A Veillette; J O'Shaughnessy; ID Horak; Mark Israel; D Yee; Neal Rosen; D J Fujita; Hsing-Jien Kung; J L Biedler; J B Bolen
Coordinate alteration of pp60c-src abundance and c-src RNA expression in human neuroblastoma variants.
Oncogene 1989;4(4):421-7.
1989: D Yee; Soonmyung Paik; G S Lebovic; R R Marcus; Roberto Favoni; Kevin J Cullen; Marc Lippman; Neal Rosen
Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer.
Molecular endocrinology (Baltimore, Md.) 1989;3(3):509-17.
1989: Kevin J Cullen; D Yee; Susan E Bates; N Brunner; Robert Clarke; R E Dickson; K K Huff; Soonmyung Paik; Neal Rosen; E Valverius
Regulation of human breast cancer by secreted growth factors.
Acta oncologica (Stockholm, Sweden) 1989;28(6):835-9.
1989: Francine M Foss; A Veillette; Oliver Sartor; Neal Rosen; J B Bolen
Alterations in the expression of pp60c-src and p56lck associated with butyrate-induced differentiation of human colon carcinoma cells.
Oncogene research 1989;5(1):13-23.
1988: D Yee; Kevin J Cullen; Soonmyung Paik; J F Perdue; Brian Hampton; A Schwartz; Marc Lippman; Neal Rosen
Insulin-like growth factor II mRNA expression in human breast cancer.
Cancer research 1988;48(23):6691-6.
1988: Marc Lippman; Robert B Dickson; Edward P Gelmann; Neal Rosen; Cornelius Knabbe; S Bates; D Bronzert; K Huff; A Kasid
Growth regulatory peptide production by human breast carcinoma cells.
Journal of steroid biochemistry 1988;30(1-6):53-61.
1987: V DeSeau; Neal Rosen; J B Bolen
Analysis of pp60c-src tyrosine kinase activity and phosphotyrosyl phosphatase activity in human colon carcinoma and normal human colon mucosal cells.
Journal of cellular biochemistry 1987;35(2):113-28.
1987: Marc Lippman; Robert B Dickson; Edward P Gelmann; Neal Rosen; Cornelius Knabbe; S Bates; D Bronzert; K Huff; A Kasid
Growth regulation of human breast carcinoma occurs through regulated growth factor secretion.
Journal of cellular biochemistry 1987;35(1):1-16.
1987: A Veillette; Francine M Foss; Edward A Sausville; J B Bolen; Neal Rosen
Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines.
Oncogene research 1987;1(4):357-74.
1987: J B Bolen; A Veillette; A M Schwartz; V Deseau; Neal Rosen
Analysis of pp60c-src in human colon carcinoma and normal human colon mucosal cells.
Oncogene research 1987;1(2):149-68.
1987: J O'Shaughnessy; V Deseau; S Amini; Neal Rosen; J B Bolen
Analysis of the c-src gene product structure, abundance, and protein kinase activity in human neuroblastoma and glioblastoma cells.
Oncogene research 1987;2(1):1-18.
1986: Neal Rosen; Charles Patrick Reynolds; Carol Jeanne Thiele; J L Biedler; Mark Israel
Increased N-myc expression following progressive growth of human neuroblastoma.
Cancer research 1986;46(8):4139-42.
1985: J B Bolen; Neal Rosen; Mark Israel
Increased pp60c-src tyrosyl kinase activity in human neuroblastomas is associated with amino-terminal tyrosine phosphorylation of the src gene product.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(21):7275-9.